LL-37 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Kills pathogens through multiple mechanisms: converts from random coil to α-helix structure, burrows into bacterial membranes causing permeabilization (carpet model), generates oxidative stress in bacterial cells, and disrupts biofilms and viral envelopes. Also immunomodulatory — activates chemokine receptors and enhances inflammatory response. Effective against 38+ bacteria, 16 fungi, and 16 viruses.
How Does LL-37 Work in the Body?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells.
Understanding its mechanism of action helps researchers design protocols and predict outcomes.
What Is the Primary Mechanism of LL-37?
Kills pathogens through multiple mechanisms: converts from random coil to α-helix structure, burrows into bacterial membranes causing permeabilization (carpet model), generates oxidative stress in bacterial cells, and disrupts biofilms and viral envelopes. Also immunomodulatory — activates chemokine receptors and enhances inflammatory response. Effective against 38+ bacteria, 16 fungi, and 16 viruses.
This mechanism operates at the cellular level and influences downstream pathways that produce the observable effects researchers study.
What Biological Pathways Does LL-37 Affect?
As a Antimicrobial peptide, host defense peptide, LL-37 interacts with specific receptors and signaling cascades. These pathways are responsible for the compound's effects on broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
The multi-pathway activity is what gives LL-37 its broad potential application range — each pathway contributes to different aspects of the overall effect profile.
How Quickly Does LL-37's Mechanism Take Effect?
With a half-life of rapidly degraded by proteases; major clinical limitation, LL-37 begins interacting with its target receptors within minutes of administration. However, the downstream biological effects take longer to manifest — typically days to weeks depending on the application.
Standard cycles run acute use as needed because that's the timeframe needed for the mechanism to produce measurable, cumulative results.
What Does the Research Say?
Achieves 3+ log reduction of S. aureus biofilms within 5 minutes at therapeutic concentrations. A derivative (omiganan/ropocamptide) advanced to late-stage clinical trials for catheter-site infections. Multiple antimicrobial peptides in this class entering human trials.
The human body's own antibiotic peptide with multiple killing mechanisms that prevent bacterial resistance development — unlike conventional antibiotics, bacteria cannot easily evolve resistance to membrane disruption.
Bottom Line on LL-37's Mechanism
LL-37 works through antimicrobial peptide, host defense peptide activity to influence broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement. Its mechanism involves multiple pathways, which is why it shows potential across several research applications.
See our LL-37 benefits guide for how this mechanism translates to practical outcomes.
Complete Guide
LL-37 : Benefits, Dosage, Side Effects & Research
Related Reading
- LL-37 Dosage Guide
- LL-37 Benefits
- LL-37 Side Effects
- LL-37 Stacking Guide
- LL-37 Cycle Guide
- LL-37 Research
Calculate Your LL-37 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for LL-37.
Open Calculator →Research-Grade Sourcing
If you're going to research LL-37, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells. It is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
What is the recommended LL-37 dosage?
Common dosages: 100-500 mcg (topical/local application) administered topical or local application as needed via topical wound application, local injection, intranasal. Cycle length: acute use as needed. Half-life: rapidly degraded by proteases; major clinical limitation. Use our peptide calculator for exact reconstitution math.
What are the side effects of LL-37?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
Is LL-37 safe?
LL-37 has shown a preliminary safety profile in research. Not FDA-approved as therapeutic. Research compound. Derivatives in late-stage clinical trials. All research should follow appropriate safety protocols.